Skip to content
CancerIndex

Publication

Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.

Authors not recorded

Clin Cancer Res2013PMID 23620406PMC3708609stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (5)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 5

Curated evidence

Evidence citing this paper (2)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
23620406
Run
ING-CIVIC-20260908-000001
Open at source CuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
PBRM1 Mutation1
(prognostic)Clear Cell Renal Cell CarcinomaPrognosticBSupports N/A3accepted
EID420

In renal clear cell carcinoma, patients with PBRM1 mutations did not have a significantly different cancer specific survival.

PMID 23620406 · Hakimi et al., 2013 · Open in CIViC

civic
VHL Mutation1
(prognostic)Clear Cell Renal Cell CarcinomaPrognosticBSupports N/A3accepted
EID422

In renal clear cell carcinoma, patients with VHL mutations did not have a significant impact on cancer specific survival.

PMID 23620406 · Hakimi et al., 2013 · Open in CIViC

civic